Consilium Medicum

2075-17532542-2170

Consilium Medicum

92872

Articles

Статьи

Research Article

Sakharnyy diabet i arterial'naya gipertoniya: epidemiologiya, prognoz i taktika antigipertenzivnoy terapii

Сахарный диабет и артериальная гипертония: эпидемиология, прогноз и тактика антигипертензивной терапии

Saygitov

R. T

Сайгитов

Р. Т

Glezer

M. G

Глезер

М. Г

Городская клиническая больница № 59, Москва

НИЦ ММА им. И.М.Сеченова

15012009

111

VOL 11, NO1 (2009)

ТОМ 11, №1 (2009)

445128122021

2009

Consilium Medicum

ООО "Консилиум Медикум"

https://creativecommons.org/licenses/by-nc-sa/4.0

https://consilium.orscience.ru/2075-1753/article/view/92872

Сахарный диабет (СД) типа II – хроническое заболевание, протекающее с гипергликемией, развивающейся вследствие резистентности периферических тканей к инсулину, недостаточности его секреции или сочетания этих состояний [1]. Пожизненный риск (lifetime risk) развития СД типа II (СДII) составляет, по некоторым оценкам, до 30–40%, т.е. диабет рано или поздно разовьется у каждого 3–4-го из 10 взрослых людей старше 25–30 лет. Распространенность артериальной гипертонии (АГ) среди населения развитых стран мира еще более значительна. Среди больных СДII частота АГ в 1,5–2 раза выше, чем в популяции.До сих пор дискутируется вопрос, насколько обоснованно проводить популяционный скрининг для раннего выявления СД еще в период его бессимптомного течения. R.Harris и соавт. (U.S. Preventive Services Task Force, 2003 г.) указывают на необходимость проведения таких мероприятий именно в группе больных АГ [14]. Выявление СД, по их мнению, приведет к снижению планки целевого уровня АД для этой когорты больных со 140/90 до 130/80 мм рт. ст. и ниже. Как результат – более «агрессивное» снижение АД (немедикаментозное или с применением антигипертензивных средств) может привести к дополнительному снижению риска развития сердечно-сосудистых событий.

Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre - diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28(1): 88–136.

Carstensen B, Kristensen J.K., Ottosen P et al. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia. 2008; 51(12): 2187–96.

Magliano D.J., Shaw J.E., Shortreed S.M. et al. Lifetime risk and projected population prevalence of diabetes. Diabetologia. 2008; 51(12): 2179–86.

Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047–53.

Протокол заседания Кардиологической секции Московского Городского научного общества терапевтов от 26.10.2006 г. http://www.zdrav.net/mgnot_protocols/26.10.2006

DECODE Study Group. Ageand sex - specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003; 26(1): 61–9.

Дедов И.И., Сунцов Ю.И., Кудрякова С.В., Рыжкова С.Г. Эпидемиология инсулиннезависимого сахарного диабета. Пробл. эндокринол. 1998. 44(3): 45–9.

Women with diabetes: quality of health care, 2004–2005. http://ahrq.hhs.gov

Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиологич. журн. 2006; 4: 45–50.

10.

Morgan C.L., Currie C.J., Peters J.R. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care. 2000; 23(8): 1103–7.

11.

Оганов Р.Г., Масленникова Г.Я. Смертность от сердечно - сосудистых и других неинфекционных заболеваний среди трудоспособного населения России. Кардиоваск. тер. и профил. 2002; 3: 4–8.

12.

Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta - analysis of 37 prospective cohort studies. BMJ 2006; 332(7533): 73–8.

13.

Глезер М.Г., Сайгитов Р.Т. Эффективность лечения артериальной гипертонии индапамидом замедленного высвобождения у мужчин и женщин в зависимости от наличия сахарного диабета 2-го типа. Результаты программы БОЛЕРО. Пробл. женск. здоровья 2008; 3(4): 5–13.

14.

Harris M.I., Klein R, Welborn T.A., Knuiman M.W. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis Diabetes Care. 1992; 15: 815–9.

15.

Jarrett R.J. Duration of non - insulin - dependent diabetes and development of retinopathy: analysis of possible risk factors. Diabet Med. 1986; 3: 261–3.

16.

Hansson L, Zanchetti A, Carruthers S.G. et al. Effects of intensive blood - pressure lowering and low - dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.

17.

Turnbull F, Neal B, Algert C et al. Effects of different blood pressure - lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005; 165(12): 1410–9.

18.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703–13.

19.

Buse J.B., Bigger J.T., Byington R.P. et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99(12A): 21i–33i.

20.

Lauritzen T, Griffin S, Borch-Johnsen K et al. The ADDITION study: proposed trial of the cost - effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24 (Suppl 3): 6–11.

21.

Sandbaek A, Griffin S.J., Rutten G et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51(7): 1127–34.

22.

Buse J.B., Ginsberg H.N., Bakris G.L. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162–72.

23.

Arauz-Pacheco C, Parrott M.A., Raskin P. Hypertension management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1): 65–7.

24.

Pi-Sunyer X, Blackburn G, Brancati F.L. et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one - year results of the look AHEAD trial. Diabetes Care 2007; 30(6): 1374–83.

25.

Egede L.E. Lifestyle modification to improve blood pressure control in individuals with diabetes: is physician advice effective? Diabetes Care 2003; 26(3): 602–7.

26.

Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72.

27.

American Diabetes Association. Standards of Medical Care in Diabetes – 2009. Diabetes Care 2009; 32 (Suppl. 1): 13–61.

28.

Whelton P.K., Barzilay J, Cushman W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005; 165(12): 1401–9.

29.

American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26: 80–2.

30.

Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87.

31.

Khan N.A., Hemmelgarn B, Herman R.J. et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 – therapy. Can J Cardiol 2008; 24(6): 465–75.

32.

Weidmann P, Boehlen L.M., de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant. 1993; 8(7): 582–4.

33.

Casas J.P., Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin - angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta - analysis. Lancet. 2005; 366(9502): 2026–33.

34.

Baguet J.P., Robitail S, Boyer L et al. A meta - analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005; 5(2): 131–40.

35.

Flack J.R., Molyneaux L, Willey K, Yue D.K. Regression of microalbuminuria: results of a controlled study, indapamide versus captopril. J Cardiovasc Pharmacol 1993; 22 (Suppl 6): 75–7.

36.

Tan S.A., Berk L.S., Tan L.G. Indapamide regresses, but transdermal clonidine does not regress, left ventricular hypertrophy in hypertensive diabetic patients. Am J Cardiol 1996; 77(6): 20–2.

37.

Kuo S.W., Pei-Dee, Hung Y.J. et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16(8): 623–8.

38.

Marre M, Puig J.G., Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22(8): 1613–22.

39.

Puig J.G., Marre M, Kokot F et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes.Am J Hypertens. 2007; 20(1): 90–7.

40.

Lievre M, Gueyffier F, Ekbom T et al. INDANA Steering Committee. Efficacy of diuretics and b - blockers in diabetic hypertensive patients: results from a meta - analysis. Diabetes Care 2000; 23 (suppl 2): 65–71.

41.

Mogensen C.E., Viberti G, Halimi S et al. Effect of low - dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41(5): 1063–71.

42.

Bakris G.L., Toto R.D., Mc Cullough P.A. et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.Kidney Int 2008; 73(11): 1303–9.

43.

Fogari R, Corradi L, Zoppi A et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens 2007; 20(10): 1092–6.

44.

Viberti G, Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure - independent effect. Circulation 2002; 106(6): 672–8.

45.

Berthet K, Neal B.C., Chalmers J.P. et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004; 13(1): 7–13.

46.

PROGRESS Collaborative Group. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–41.

47.

PATS Collaborating Group. Post - stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108(9): 710–7.

48.

Patel A, Mac Mahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829–40.